Who are 131I's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PET Scan with [18F] VAT, [Ga-68]PSMA, strontium-89, Dexamethasone plus Radium-223, Radium-223, Rubidium-82.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/131i.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

131I — Competitive Intelligence Brief

131I (131I) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical. Area: Oncology.

phase 2 Radiopharmaceutical Sodium-iodide symporter (NIS) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

131I (131I) — Genzyme, a Sanofi Company. Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid tissue and thyroid cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
131I TARGET	131I	Genzyme, a Sanofi Company	phase 2	Radiopharmaceutical	Sodium-iodide symporter (NIS)
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
strontium-89	strontium-89	Alberta Health services	marketed	Radiopharmaceutical; bone-seeking radioisotope	Hydroxyapatite in bone matrix; osteoblast uptake
Dexamethasone plus Radium-223	Dexamethasone plus Radium-223	University Health Network, Toronto	marketed	Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical	Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor
Radium-223	radium-223	Pfizer	marketed	Radiopharmaceutical	Bone cells
Rubidium-82	Rubidium-82	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	marketed	PET radiopharmaceutical	Na+/K+-ATPase pump (myocardial uptake mechanism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical class)

Amsterdam UMC, location VUmc · 1 drug in this class
Blue Earth Diagnostics · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
IRCCS San Raffaele · 1 drug in this class
ITEL Telecomunicazioni Srl · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Michael C Roarke, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 131I — Competitive Intelligence Brief. https://druglandscape.com/ci/131i. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab